Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
RIGL Stock | USD 27.61 0.27 0.97% |
About 51% of Rigel Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Rigel Pharmaceuticals suggests that many traders are impartial. Rigel Pharmaceuticals' investing sentiment shows overall attitude of investors towards Rigel Pharmaceuticals.
Rigel |
Rigel Pharmaceuticals, Inc. today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology Annual Meeting and European Hematology Association 2024 Hybrid Congress. The ASCO Annual Meeting is being held online and in person in Chicago, Illinois from May 31 to June 4, 2024. The EHA2024 Congress is being held online and in person in Madrid, Spain from June 13 to June 16,
Read at finance.yahoo.com
Rigel Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rigel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rigel Pharmaceuticals Fundamental Analysis
We analyze Rigel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Rigel Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Rigel Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rigel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Rigel Pharmaceuticals Related Equities
FBIO | Fortress Biotech | 16.39 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
IMMX | Immix Biopharma | 7.11 | ||||
ELEV | Elevation Oncology | 3.23 | ||||
ENVB | Enveric Biosciences | 3.13 | ||||
LPTX | Leap Therapeutics | 2.05 | ||||
ZURA | Zura Bio | 1.67 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
CDTX | Cidara Therapeutics | 0.05 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
PIRS | Pieris Pharmaceuticals | 3.45 |
Check out Rigel Pharmaceuticals Hype Analysis, Rigel Pharmaceuticals Correlation and Rigel Pharmaceuticals Performance. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.